Glenmark Gains USFDA Approval for OTC Nasal Spray and Launches Generic Milnacipran Tablets
2 hours agoBusiness
34LENS
2 SourcesUnited States
TBNthebalanced.news

Glenmark Gains USFDA Approval for OTC Nasal Spray and Launches Generic Milnacipran Tablets

Glenmark Pharmaceuticals has received USFDA approval for its Fluticasone Propionate Nasal Spray (OTC), entering the US over-the-counter nasal spray market with a product bioequivalent to Flonase Allergy Relief. The nasal spray launch is planned for April 2026. Additionally, Glenmark Pharmaceuticals Inc., USA, has launched Milnacipran Hydrochloride Tablets in multiple strengths as an authorized generic version of Savella Tablets, targeting a market with annual sales of approximately $102.9 million.

Political Bias
0%100%0%
Sentiment
72%
21 stories available
View AI Analysis

Bias Analysis: The articles focus on Glenmark Pharmaceuticals' regulatory approvals and product launches without political framing. Coverage centers on business developments and market data, reflecting a neutral, industry-focused perspective. There is no evident political bias, as the content emphasizes corporate milestones and market opportunities rather than political or ideological viewpoints.

Sentiment: The tone across the articles is positive and factual, highlighting Glenmark's regulatory success and market entry. The coverage emphasizes growth potential and product launches without critical or negative commentary, resulting in an overall optimistic sentiment regarding the company's expansion in the US pharmaceutical market.

Lens Score: 34/100 — Story is well-covered by media outlets. Public interest: 0/100. Coverage gap: 100%.